

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

**DRUG REGISTRATION APPROVAL OF
“FOSAPREPITANT DIMEGLUMINE FOR INJECTION”**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that “fosaprepitant dimeglumine for injection” (product name “**Tanneng**” (坦能)) developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (江蘇豪森藥業集團有限公司), a subsidiary of the Company, has been granted drug registration approval by the National Medical Products Administration of the People’s Republic of China and obtained approval for marketing.

As a drug urgently needed in clinical practice, fosaprepitant dimeglumine has been included in the “List of First Batch of Encouraged Generic Drugs” (《第一批鼓勵仿製藥品目錄》) of the People’s Republic of China. Tanneng is the first and currently only domestic fosaprepitant dimeglumine that has obtained approval for marketing. It was filed as a Category 3 new chemical drug and is considered to have passed the consistency evaluation.

Tanneng is used for the prevention of acute and delayed nausea and vomiting caused by chemotherapy, and its obtaining of approval for marketing will further enrich and improve the oncology product pipeline of the Group.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, October 16, 2019

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, Ms. Ma Cuifang as non-executive director, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.